Verapamil Disposition Kinetics in Chronic Atrial Fibrillation
Overview
Affiliations
Verapamil disposition was studied in 12 patients with chronic and fibrillation. After an intravenous bolus of 15 mg plasma concentration was determined and the data fit in a three-compartment model. Model independent parameters were calculated and values for half-life (t 1/2), clearance, and steady-state distribution volume were 6.3 +/- 4 hr, 13.3 +/- 7.7 ml/min/kg, and 4.3 +/- 1.9 l/kg. The model was used to design a multistep infusion scheme, which was employed successfully to achieve predetermined plasma concentrations. Following single oral doses of 120 mg, plasma levels of verapamil and norverapamil were determined. The elimination t 1/2 for verapamil and norverapamil were 8.3 +/- 6.1 and 10.5 +/- 5.6 hr, respectively. The bioavailability of oral verapamil was 35 +/- 16%. During long-term oral therapy the mean verapamil plasma concentration was twice the value predicted from the single-dose studies. This suggests that verapamil may have reduced clearance during long-term oral use.
A Dose-Finding Study to Guide Use of Verapamil as an Adjunctive Therapy in Tuberculosis.
Padmapriyadarsini C, Szumowski J, Akbar N, Shanmugasundaram P, Jain A, Bathragiri M Clin Pharmacol Ther. 2023; 115(2):324-332.
PMID: 37983978 PMC: 7615557. DOI: 10.1002/cpt.3108.
Trenaman S, Bowles S, Andrew M, Goralski K Pharmacol Res Perspect. 2021; 9(3):e00775.
PMID: 34003603 PMC: 8130657. DOI: 10.1002/prp2.775.
Sex and gender differences in polypharmacy in persons with dementia: A scoping review.
Trenaman S, Rideout M, Andrew M SAGE Open Med. 2019; 7:2050312119845715.
PMID: 31041100 PMC: 6477755. DOI: 10.1177/2050312119845715.
Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men.
Umeh O, Currier J, Park J, Cramer Y, Hermes A, Fletcher C J Clin Pharmacol. 2011; 51(12):1665-73.
PMID: 21233301 PMC: 3325020. DOI: 10.1177/0091270010388650.
Validation of the hepatic blood flow rate model for verapamil first-pass metabolism.
Popovic J Eur J Drug Metab Pharmacokinet. 2007; 32(1):13-9.
PMID: 17479539 DOI: 10.1007/BF03190985.